173 related articles for article (PubMed ID: 30858922)
1. The interplay of CDK4 and CDK6 in melanoma.
Kollmann K; Briand C; Bellutti F; Schicher N; Blunder S; Zojer M; Hoeller C
Oncotarget; 2019 Feb; 10(14):1346-1359. PubMed ID: 30858922
[TBL] [Abstract][Full Text] [Related]
2. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
Paternot S; Colleoni B; Bisteau X; Roger PP
Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
[TBL] [Abstract][Full Text] [Related]
3. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.
Zanuy M; Ramos-Montoya A; Villacañas O; Canela N; Miranda A; Aguilar E; Agell N; Bachs O; Rubio-Martinez J; Pujol MD; Lee WN; Marin S; Cascante M
Metabolomics; 2012 Jun; 8(3):454-464. PubMed ID: 22661920
[TBL] [Abstract][Full Text] [Related]
6. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
Rodríguez-Díez E; Quereda V; Bellutti F; Prchal-Murphy M; Partida D; Eguren M; Kollmann K; Gómez de Cedrón M; Dubus P; Cañamero M; Martínez D; Sexl V; Malumbres M
Blood; 2014 Oct; 124(15):2380-90. PubMed ID: 25157181
[TBL] [Abstract][Full Text] [Related]
7. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
8. Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
Zhang Z; Golomb L; Meyerson M
Cancer Res; 2022 Jun; 82(11):2171-2184. PubMed ID: 35395071
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic stimulation recruits cyclin-dependent kinase in the cell cycle start in rat fibroblast.
Jinno S; Hung SC; Yamamoto H; Lin J; Nagata A; Okayama H
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13197-202. PubMed ID: 10557297
[TBL] [Abstract][Full Text] [Related]
10. Lack of germline CDK6 mutations in familial melanoma.
Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
[TBL] [Abstract][Full Text] [Related]
11. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.
Scheicher R; Hoelbl-Kovacic A; Bellutti F; Tigan AS; Prchal-Murphy M; Heller G; Schneckenleithner C; Salazar-Roa M; Zöchbauer-Müller S; Zuber J; Malumbres M; Kollmann K; Sexl V
Blood; 2015 Jan; 125(1):90-101. PubMed ID: 25342715
[TBL] [Abstract][Full Text] [Related]
12. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.
Malumbres M; Sotillo R; Santamaría D; Galán J; Cerezo A; Ortega S; Dubus P; Barbacid M
Cell; 2004 Aug; 118(4):493-504. PubMed ID: 15315761
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
De Dominici M; Porazzi P; Xiao Y; Chao A; Tang HY; Kumar G; Fortina P; Spinelli O; Rambaldi A; Peterson LF; Petruk S; Barletta C; Mazo A; Cingolani G; Salvino JM; Calabretta B
Blood; 2020 Apr; 135(18):1560-1573. PubMed ID: 32040545
[TBL] [Abstract][Full Text] [Related]
14. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor of activated T cells c1 mediates p21-activated kinase 1 activation in the modulation of chemokine-induced human aortic smooth muscle cell F-actin stress fiber formation, migration, and proliferation and injury-induced vascular wall remodeling.
Kundumani-Sridharan V; Singh NK; Kumar S; Gadepalli R; Rao GN
J Biol Chem; 2013 Jul; 288(30):22150-62. PubMed ID: 23737530
[TBL] [Abstract][Full Text] [Related]
16. The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.
Iida M; Nakamura M; Tokuda E; Toyosawa D; Niwa T; Ohuchi N; Ishida T; Hayashi SI
Oncotarget; 2019 Aug; 10(47):4907-4918. PubMed ID: 31448056
[TBL] [Abstract][Full Text] [Related]
17. CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in
Schneeweiss-Gleixner M; Filik Y; Stefanzl G; Berger D; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Witzeneder N; Greiner G; Hoermann G; Schiefer AI; Schwaab J; Jawhar M; Reiter A; Sperr WR; Arock M; Valent P; Gleixner KV
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804842
[TBL] [Abstract][Full Text] [Related]
18. Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation.
Murphy JM; Jeong K; Ahn EE; Lim SS
J Biol Chem; 2022 Jun; 298(6):102013. PubMed ID: 35525274
[TBL] [Abstract][Full Text] [Related]
19. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
[TBL] [Abstract][Full Text] [Related]
20. CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.
Tigan AS; Bellutti F; Kollmann K; Tebb G; Sexl V
Oncogene; 2016 Jun; 35(24):3083-91. PubMed ID: 26500059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
